Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Somira Health vs Welling Health

By GLP-1 ScorecardUpdated

Somira Health
Site position #304

Lower grade

Welling Health
Site position #166

Higher grade

Score comparison

Welling Health has the higher recorded score — 68.3/100 to 62.5/100.

Welling Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Welling Health is a clinician-led metabolic clinic offering compounded GLP-1 therapy on one transparent flat monthly rate: semaglutide from $190/month and tirzepatide from $275/month, with all doses, clinician access, free shipping and a free AI macro-tracker app included.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueWelling Health +4
52
56
Dose & formulationEven
64
64
Clinical oversightWelling Health +12
77
89
Labs & monitoringSomira Health +8
62
54
FulfillmentWelling Health +10
83
93
Contract termsWelling Health +30
25
55
Somira Health · top barWelling Health · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricSomira HealthWelling Health
WeighScore62.5/10068.3/100
GradeCC
Site position#304#166
Semaglutide$190/mo (compounded)$190/mo (compounded)
Tirzepatide$285/mo (compounded)$275/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Somira Health

Site position #304 · C

Strengths

  • Transparent flat monthly pricing that does not increase as you titrate (semaglutide $189.99/mo, tirzepatide $284.99/mo)
  • Quarterly plans lower the effective monthly cost (semaglutide $136.66/mo, tirzepatide $221.66/mo)
  • Free overnight shipping, with syringes and alcohol wipes included in every order
  • Simple, fast online intake reviewed by a licensed provider; no insurance required
  • Both weekly compounded GLP-1 options offered: semaglutide and tirzepatide

What to consider

  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named
  • State-availability list is not published
  • No LegitScript certification displayed
  • New, thin platform with limited public detail on the provider network, lab monitoring, or ongoing support
Welling Health

Site position #166 · C

Strengths

  • Transparent flat monthly rate — $190 semaglutide / $275 tirzepatide, all doses, no insurance or hidden fees
  • LegitScript-certified 503A pharmacy with US-licensed clinicians in all 50 states and a named legal entity
  • Streak discounts cut up to 30% — semaglutide as low as $133/month for logging meals consistently
  • Free shipping, free AI macro-tracker app, and 24-hour intake review

What to consider

  • Tirzepatide at $275/month is higher than the cheapest compounded competitors
  • The streak discount requires daily in-app meal logging — miss days and you pay full rate
  • The compounding pharmacy partner is described as a LegitScript-certified 503A but not named
  • Only two medications — compounded semaglutide and tirzepatide; no oral or non-GLP options

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard